Kiniksa PharmaceuticalsKNSA
13F holders, Q3 2024 (September 30)2holders −3
1new positions
4sold out
$24.99avg. 13F price*
At the end of Q3 2024, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, down 3 from Q2 2024. 1 opened new positions and 4 sold out. The largest holders were Harbor Capital Advisors, Inc. ($2.4M) and Birchview Capital, LP ($750K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2.4M |
| Exits | 4 | $686K |
All 13F filers, Q2 2024 → Q3 2024: 97,543 shares bought and 36,788 shares sold, net +60,755 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Harbor Capital Advisors, Inc. | 0.11% | New | 97,543 | $2.4M |
| Birchview Capital, LP | 0.65% | No change | 30,000 | $750K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.